China’s healthcare index sinks 7.1% as investors pivot to tech AI

The sector’s stocks lag as AI inflows reshaped sector allocation patterns.

China’s Hang Seng Healthcare Index fell 7.1% between 14 April and 14 May 2026, underperforming the Hang Seng Index, which rose 2.0% over the same period, as capital rotated into technology and artificial intelligence stocks.

Whilst the sector maintained an “overweight” rating, UOB Kay Hian said in a report that the healthcare index’s decline reflects investor rotation rather than sector-wide earnings deterioration.

It said fundamentals remain supported by innovation, globalisation, and policy direction, with resilient revenue and earnings growth expected into 2026 and beyond.

Biopharmaceutical and medical technology companies reported mixed first-quarter 2026 results, with stronger performance from innovation-led and globally exposed firms, whilst traditional and policy-sensitive segments showed margin pressure.

The report said demand for high-end medical products and overseas expansion continued to support growth for drug innovators and medical technology companies.

Policy developments from the National Healthcare Security Administration include draft rules for 2026 National Reimbursement Drug List and Commercial Insurance Innovative Drug List negotiations.

The proposals introduce pre-submission requirements for innovative drugs and tighter renewal and pricing rules for products listed for more than eight years.

The report said these changes could accelerate reimbursement access for new therapies whilst increasing price pressure on mature drugs.

The traditional Chinese medicine segment faces additional pressure from pricing controls, including zero mark-up requirements for formula granules and government procurement tenders.

Chinese biopharma companies recorded stronger sales momentum alongside increased licensing activity and new regulatory approvals, reinforcing pipeline-driven revenue expansion.

The report cited innovation pipelines, commercial expansion, global partnerships, and policy support for innovative drugs as key catalysts.

It flagged geopolitical tensions, regulatory changes, economic weakness, research and development risk, competition, and overseas expansion execution as risks.